GNAO1 antisense RNA 1 (GNAO1-AS1)

GNAO1 antisense RNA 1 (GNAO1-AS1), also referenced as GNAO1 divergent transcript or GNAO1-DT, is a long non-coding RNA transcribed antisense to the protein-coding GNAO1 gene. Unlike the canonical GNAO1 gene products, which encode critical G protein alpha subunits involved in signal transduction and linked to pediatric neurodevelopmental syndromes[1][2][3], GNAO1-AS1 has no confirmed protein product and its biological roles have not been clearly delineated in the scientific literature. There is little evidence that it serves as a direct therapeutic target, biomarker, or is implicated in disease mechanisms distinct from its possible regulation of GNAO1 expression. Key issues and clarification: - The vast majority of the clinical and biochemical literature about “GNAO1” concerns the protein-coding gene (G protein subunit alpha O1), not the antisense or divergent transcript[1][2][3]. - The term “GNAO1 divergent transcript” or “GNAO1-DT” refers to an antisense non-coding RNA, which is not a validated therapeutic target (unlike receptors, enzymes, channels, etc.). - No drug is known to interact with GNAO1-AS1 or GNAO1-DT, nor is there mechanistic or clinical characterization matching that for canonical protein targets[3]. Because GNAO1-DT is not a therapeutic target and its biological role remains poorly characterized, is_target is set to “false” and is_incorrect is set to “true” for queries about it as a receptor or protein target. If you intended to request information about the actual protein-coding GNAO1 gene, please clarify; that molecule is a major therapeutic and disease gene implicated in neurodevelopmental disorders[1][2][3].

Other names

GNAO1 divergent transcriptGNAO1-DTGNAO1-AS1GNAO1 antisense RNA 1